Nav: Home

New HPV vaccine could curb cervical cancers and health costs if adopted widely

April 18, 2016

New Haven, Conn.-- A Yale-led study finds that a new vaccine for human papillomavirus (HPV) would significantly reduce both cervical cancer incidence and healthcare costs if states coordinated policies to improve coverage.

The study was published April 18 by Proceedings of the National Academy of Sciences.

HPV, the most common sexually transmitted infection in the United States, is the primary cause of cervical cancer. A new vaccine available since 2015, Gardasil 9, provides protection against nine different HPV types, including five cancer-causing types that were not included in older vaccines. A team of researchers at Yale School of Public Health and the University of Waterloo developed a transmission model to determine the potential impact of the vaccine on cervical cancer incidence and healthcare costs.

The novel model took into account several factors affecting HPV transmission and cervical cancer progression. It incorporated 10 HPV types, demographics, age, sexual behavior, as well as state-specific vaccine policy and migration patterns.

The researchers found that switching to Gardasil 9 would result in greater health benefits at the same or lower cost. Specifically, the new vaccine would decrease cervical cancer incidence by 73%, compared to 63% with the older vaccines, and reduce mortality by 49% versus 43%.

The study also determined that these improvements could be realized at the same or lower cost despite the higher per-dose cost of Gardasil 9. Notably, their finding of increased cost-effectiveness holds whether vaccination rates increase or stay the same, said first author David Durham, associate research scientist at the Center for Infectious Disease Modeling and Analysis (CIDMA) at Yale School of Public Health. "Adopting the new vaccine is always cost-effective relative to the old vaccines," he noted.

In addition, efforts to expand HPV vaccination, particularly in states with low coverage, could prevent even more cancers and deaths, said the researchers, adding that due to interstate migration, all states would benefit if they aligned vaccination policy. "The greatest benefits of HPV vaccination both in terms of cancer reduction and health care costs are realized when policy promoting vaccination is coordinated across states," said Alison Galvani, the Burnett and Stender Families Professor of Epidemiology and director of CIDMA.

Furthermore, increased funding to states could improve vaccine coverage and public health, the researchers noted. Durham pointed to funds provided by states and the Centers for Disease Control and Prevention's (CDC) Prevention and Public Health Fund. More resources "do lead to improvements in coverage," he said. "In terms of number of cancers averted per vaccine, there are decreasing marginal returns in states that already have high coverage. You get more bang for your buck by focusing first on states with lower coverage."

The CDC currently recommends vaccination for females aged 11-26 and males aged 11-21. Three doses are recommended for lasting protection against cervical cancer, the researchers said. HPV is common in both males and females, and can cause cancers of the anus, mouth/throat and penis in males.
-end-
Additional study authors include Martial Loth Ndeffo Mbah, Laura A. Skrip, Forrest K. Jones, and Chris T. Bauch.

This research was funded by the National Institutes of Health, the James S. McDonnell Foundation, and the Canadian Institutes of Health Research.

Citation: Proceedings of the National Academy of Sciences

Yale University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...